MitoMarkers: Mitochondrial Dysfunction in Autism
Summary
Autism spectrum disorder is a neurodevelopmental disorder affecting 1 in 54 children in Canada. ASD is increasingly being associated with mitochondrial dysfunction, a condition that may intensify or influence ASD symptoms. Mitochondrial dysfunction in ASD can impact various biological processes, that influence the neurodevelopmental aspects of the disorder. This connection suggests that mitochondrial health may play a crucial role in the manifestation of ASD's core symptoms, such as difficulties in social interaction, communication challenges, and repetitive behavior patterns. Given the potential link between mitochondrial dysfunction and ASD, this study aims to utilize buccal swab samples to assess mitochondrial health in individuals with ASD. By analyzing mitochondrial function in a sample that is easy to obtain and does not cause harm is invasive, the study hopes to better understand the role of mitochondrial dysfunction in ASD. Our improved understanding of mitochondria function in ASD can lead to better and more effective ways to manage symptoms that create day-to-day set backs in an individuals life and creater more tailored intervention stategies.
Eligibility
Eligible ages: 5 to 17
Accepts healthy participants: Yes
Inclusion criteria:
ASD Group:
1) Children aged 5-17 at the time of the visit with a diagnosis of autism and seen in consultation at the Child Development Centre.
2) Signed inform consent.
3) Willing & able to comply with study procedures
Control Group (Age-matched, sibling)
1) Aged 5-17yrs old
2) Parental consent and/or child assent
3) Willing & able to comply with study procedures
Exclusion criteria:
1) Antibiotic use 4 weeks prior to testing
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Tina Ram
Principal investigator:
Jane Shearer, Vice-Chair
Clinical trial:
No
REB-ID:
REB23-1557